This Week In Cardiology

The Excel trial, peripartum cardiomyopathy, marathoning, hot-spotting, and leadership in innovation are the topics discussed by Dr. John Mandrola in this week’s podcast.

The EXCEL debate, the NOBLE trial, alcohol and AF, cardiac devices, and hospital consolidation are the topics covered by John Mandrola, MD, in this week’s podcast.

A risk score for device infection, conflicts of interest, the Fragility Index, rhythm vs rate control for AF in HFpEF, and year-end highlights are discussed by John Mandrola, MD, in this week's podcast.

The EXCEL trial controversy, and Dr John Mandrola's experience with vernakalant at FDA are the topics covered in this week's podcast.

Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week’s podcast.

Highlights from the 2019 AHA meeting are analyzed by Dr John Mandrola in this week’s podcast.

Interruption of oral anticoagulation, marijuana and stroke, ORBITA substudy, ISCHEMIA medical therapy targets, and more on AHA are the topics discussed by Dr. John Mandrola in this week’s podcast.

Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week’s podcast.

Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week’s podcast.

AF after TAVR, opioids after cardiac devices, hypertension in black adults, and post-cardiac surgery AF are the topics Dr John Mandrola discusses in this week’s podcast.

The Nobel Prize, more on the EXCEL trial, the costs of cardiac tests, familial hypercholesterolemia, and burnout are the topics discussed by Dr John Mandrola in this week’s podcast.

Left main PCI vs CABG trials and TAVR vs SAVR—in this week’s podcast, Dr John Mandrola takes a deeper dive.

Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week’s podcast.

The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week’s podcast.

More from ESC: Antiplatelets and NOACs, blood glucose control, high sensitivity troponin tests, and ICD trials are all covered by John Mandrola, MD, in this week’s podcast.

Six major trials from the ESC meeting in Paris are reviewed by John Mandrola, MD, in this week’s podcast.

Digital health, a new LDL-c lowering drug, PCSK9i outcomes in higher risk patients, and an ESC preview are discussed by John Mandrola in this week’s podcast.

TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week’s podcast.

AI for AF detection, syncope and PE, thoracentesis, fish oil, and why doctors should organize are the topics covered by John Mandrola in this week’s podcast.

Digoxin, acupuncture and angina, heart failure with preserved ejection fraction, bariatric surgery, and cardiac device complications are the topics John Mandrola covers in this week's podcast.